Academic Grant Programs
Academic Grant Programs
The Leukemia & Lymphoma Society's academic grants support and encourage basic, translational, and clinical blood cancer research.
LLS investigators are outstanding scientists at the forefront of research into hematologic malignancies at centers throughout the world. We award academic grants for studies that range from basic blood cancer discovery science to research that uses the latest tools of genomics.
And we don't stop there. We're also dedicated to funding blood cancer research to help improve the quality of life for patients and their families with our projects studying long-term and late effects.
Get to know some of our Current Grantees and our Current Projects on the main program pages!
You can contact us at researchprograms@lls.org if you have any questions.
Specialized Center of Research Program (SCOR)
Bringing together established investigators to develop a focused research program, foster new interactions and cooperation, as well as enhance interdisciplinary research.
PROGRAM OPEN
Go directly to the information page on the SCOR application process or
browse our resources for current SCOR awardees.
Underrepresented Minority Medical Student Research Program
Providing minority medical students with opportunities to experience cutting-edge research alongside experienced blood cancer scientists.
PROGRAM OPEN!
Career Development Program (CDP)
Supporting talented young early-career physicians and scientists.
Go directly to the CDP application process page to apply, browse our
resources for current CDP awardees or find out more about the CDP Achievement Awards.
Academic Clinical Trials Program (ACT)
Developing cutting edge treatments that will have meaningful impact for blood cancer patients through academic investigator initiated clinical trials.
Go directly to the ACT application process page to apply.
Discovery Grant Program (DGP)
Supporting cutting edge, innovative and discovery oriented research, to understand blood cancer properties and vulnerabilities and aimed toward advancing treatments for blood cancers.
Go directly to the information page on the Discovery application process or
browse our resources for current Discovery awardees.
Research Accelerator for Follicular Lymphoma I (RAFL-I)
The Research Accelerator for Follicular Lymphoma I (RAFL-I) supports targeted research to better understand disease mechanisms, develop more efficacious treatments and improve the outcome for Follicular Lymphoma patients.
CMML Special Initiative
Expanding research in Chronic Myelomonocytic Leukemia to better characterize its biology, develop new therapies, and optimize outcomes for patients.
Translational Research Program (TRP)
Funding new and innovative research that shows high promise for translating basic biomedical knowledge to clinical application: "Bench-to-Bedside".
Equity in Access Research Grants
Supporting the generation of evidence that will guide changes in healthcare policy and practice to ensure that all patients with and survivors of a blood cancer achieve access to the cancer care and services they need throughout their lives.
Influential Medicine Providing Access to Clinical Trials (IMPACT)
Bringing leading-edge clinical trials to the patient.
Go directly to the information page on the IMPACT application process or
browse our resources for current IMPACT awardees.
HCL2025
The HCLF and LLS joining forces to expanding research in Hairy Cell Leukemia to better characterize its biology, develop new therapies, and optimize outcomes for patients.
Download the 2019 Request For Proposals or
view our Statement on Future Research and Therapies for HCL.
RTFCCR/LLS Cancer Prevention Research Grant for Blood Cancer
The Rising Tide Foundation for Clinical Cancer Research and LLS partner in an international competitive grant to advance breakthroughs in prevention for blood cancers.
Go directly to the information page on the Prevention Awards or
browse our resources for current Prevention awardees.
Mantle Cell Lymphoma Research Initiative II (MCL2)
The Mantle Cell Lymphoma Research Initiative II supports targeted research to better understand disease mechanisms, develop more efficacious treatments and improve the outcome for MCL patients.